4 weeks Merck to Report Q3 Earnings: To Buy or Not to Buy MRK Stock?Zacks
Investor focus is likely to be on the sales of Merck’s blockbuster oncology medicine, Keytruda, when the company reports third-quarter earnings.
XInvestor focus is likely to be on the sales of Merck’s blockbuster oncology medicine, Keytruda, when the company reports third-quarter earnings.
X